Sichenzia Ross Ference Kesner LLP Represents Cannabinoid Based Therapeutics Company in $12.3 Million Private Placement Led by Tuatara Capital Fund I, Ltd.
Press Release – New York, NY – March 2, 2017 – Securities and corporate law firm Sichenzia Ross Ference Kesner LLP is pleased to announce that the firm has represented a cannabinoid based life sciences corporation whose technology is designed to synthetically produce medically beneficial cannabinoids without utilizing the actual cannabis plant for the customized treatment of disease.
Last year, Tuatara and its affiliates invested $7.0 million in a Series A Financing for the company. The Sichenzia Ross Ference Kesner LLP team was led by partners Darrin M. Ocasio and Arthur Marcus and associate S. Ashley Jaber. Sichenzia Ross Ference Kesner LLP is a leader in the representation of cannabis related companies.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Medical Marijuana Dispensary Business Project 1493, LLC Announces Share Exchange Agreement with Public Entity & Simultaneous $3.3 Million PIPE Financing - June 16, 2017
- Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing - June 15, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar, and Fordham Financial Management in $6.6 Registered Direct offering of Ampio Pharmaceuticals, Inc. - June 8, 2017